Sai-Hong Ignatius Ou
University of California, Irvine
H-index: 95
North America-United States
Top articles of Sai-Hong Ignatius Ou
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
A pragmatic guide for management of adverse events associated with lorlatinib | Geoffrey Liu Julien Mazieres Jan Stratmann Sai-Hong Ignatius Ou Tony Mok | 2024/3/15 | |
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC | Journal of Thoracic Oncology | Lanyi Nora Chen Alexandria TM Lee Misako Nagasaka Sai-Hong Ignatius Ou | 2024/3/1 |
MARIPOSA-2: Is the treatment worse than the disease? | Med | Alexandria TM Lee Sai-Hong Ignatius Ou | 2024/2/9 |
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data | Misako Nagasaka Danielle Brazel Sai-Hong Ignatius Ou | 2024/2/1 | |
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer | Clinical Pharmacokinetics | Joseph Chen Alessandra Bearz Dong-Wan Kim Hirva Mamdani Jessica Bauman | 2024/2 |
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet … | Lung Cancer: Targets and Therapy | Alexandria TM Lee Sai-Hong Ignatius Ou | 2024/12/31 |
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial | Nature Medicine | Jayesh Desai Guzman Alonso Se Hyun Kim Andres Cervantes Thomas Karasic | 2024/1 |
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients | Clinical Cancer Research | Cloud P Paweletz Grace A Heavey Yanan Kuang Emily Durlacher Thian Kheoh | 2023/8/15 |
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing | BMC cancer | Misako Nagasaka Shannon S Zhang Yasmine Baca Joanne Xiu Jorge Nieva | 2023/10/18 |
Stage as the Sole Biomarker for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and … | Saihong Ou Misako Nagasaka | 2023 | |
OA16. 04 Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS) | Journal of Thoracic Oncology | Elaine Shum Wenyuan Li J Bell L Sequist S-HI Ou | 2023/11/1 |
Abstract C020: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors | Molecular Cancer Therapeutics | Alison M Schram Abdul Rafeh Naqash Eric B Haura Jonathan W Riess Susanna V Ulahannan | 2023/12/1 |
Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer | Kaleem Anwar Lee Nguyen Misako Nagasaka Sai-Hong Ignatius Ou Alexandre Chan | 2023/2/1 | |
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations | Lung Cancer | Petros Christopoulos Thibaud Prawitz Jin-Liern Hong Huamao M Lin Luis Hernandez | 2023/5/1 |
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and … | Lung Cancer: Targets and Therapy | Misako Nagasaka Saihong Ignatius Ou | 2023/12/31 |
NRG1 Fusions in Solid Tumors | Breast | Brinda Gupta Sharon Wu Sai-Hong Ignatius Ou Sourat Darabi Kathryn F Mileham | 2023/6/1 |
A comprehensive survey of tumor mutation burden (TMB) using the AACR GENIE cbioportal database: Pathogenesis of NTRK and RET fusion (NTRK+/RET+) positive colorectal (CRC). | Zhaohui Arter Alexandria TM Lee Misako Nagasaka Sai-Hong Ignatius Ou | 2023/8 | |
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. | Danielle Brazel Yasmine Baca Joanne Xiu Mohammed Al-Hallak Chul Kim | 2023/10/1 | |
Lung Cancer: Targets and Therapy Dove press | Danielle Brazel Saihong Ignatius Ou | 2023 | |
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a towering inferno | Danielle Brazel Sai-Hong Ignatius Ou Misako Nagasaka | 2023/12/31 |
